ADCT vs. AKBA, NRIX, AVXL, IMNM, RCKT, AVBP, DAWN, TRVI, IMTX, and VIR
Should you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Akebia Therapeutics (AKBA), Nurix Therapeutics (NRIX), Anavex Life Sciences (AVXL), Immunome (IMNM), Rocket Pharmaceuticals (RCKT), ArriVent BioPharma (AVBP), Day One Biopharmaceuticals (DAWN), Trevi Therapeutics (TRVI), Immatics (IMTX), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry.
ADC Therapeutics vs.
ADC Therapeutics (NYSE:ADCT) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, community ranking, valuation, dividends and media sentiment.
ADC Therapeutics presently has a consensus price target of $7.75, indicating a potential upside of 296.42%. Akebia Therapeutics has a consensus price target of $6.63, indicating a potential upside of 135.77%. Given ADC Therapeutics' higher possible upside, research analysts clearly believe ADC Therapeutics is more favorable than Akebia Therapeutics.
Akebia Therapeutics has a net margin of -27.07% compared to ADC Therapeutics' net margin of -300.00%.
ADC Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.
Akebia Therapeutics has higher revenue and earnings than ADC Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, ADC Therapeutics had 9 more articles in the media than Akebia Therapeutics. MarketBeat recorded 13 mentions for ADC Therapeutics and 4 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 1.46 beat ADC Therapeutics' score of 0.48 indicating that Akebia Therapeutics is being referred to more favorably in the news media.
Akebia Therapeutics received 359 more outperform votes than ADC Therapeutics when rated by MarketBeat users. However, 69.23% of users gave ADC Therapeutics an outperform vote while only 63.08% of users gave Akebia Therapeutics an outperform vote.
41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 4.1% of ADC Therapeutics shares are owned by insiders. Comparatively, 3.0% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Akebia Therapeutics beats ADC Therapeutics on 10 of the 18 factors compared between the two stocks.
Get ADC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADC Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:ADCT) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy ADCT Stock Free ADCT Stock Alerts